• Publications
  • Influence
Convergent Antibody Responses to SARS-CoV-2 in Convalescent Individuals
TLDR
Most convalescent plasma samples obtained from individuals who recover from COVID-19 do not contain high levels of neutralizing activity, and rare but recurring RBD-specific antibodies with potent antiviral activity were found in all individuals tested, suggesting that a vaccine designed to elicit such antibodies could be broadly effective.
SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies
TLDR
Eight new structures of distinct COVID-19 human neutralizing antibodies 5 in complex with the SARS-CoV-2 spike trimer or RBD are solved and rules for assigning current and future human RBD-targeting antibodies into classes, evaluating avidity effects and suggesting combinations for clinical use are provided.
Deep-sequencing identification of the genomic targets of the cytidine deaminase AID and its cofactor RPA in B lymphocytes
TLDR
It is proposed that stalled polymerases recruit AID, thereby resulting in low frequencies of hypermutation across the B cell genome, and provides a rationale for the oncogenic role of AID in B cell malignancy.
Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants
TLDR
It is shown that functional SARS-CoV-2 S protein variants with mutations in the receptor binding domain (RBD) and N-terminal domain that confer resistance to monoclonal antibodies or convalescent plasma can be readily selected.
Evolution of Antibody Immunity to SARS-CoV-2
TLDR
The memory B cell response to SARS-CoV-2 evolves between 1.3 and 6.2 months after infection in a manner that is consistent with antigen persistence, and the antibodies they express have greater somatic hypermutation, increased potency and resistance to RBD mutations, indicative of continued evolution of the humoral response.
...
...